SCHEMBL793794

SCHEMBL793794

Cc1ccncc1N1C(=O)c2cc(C(F)(F)F)ccc2CC1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.41
HTR2C P28335 3/20 0.41
HTR2B P41595 2/20 0.41
CYP11B2 P19099 1/20 0.40
GRM2 Q14416 5/20 0.38
PDE10A Q9Y233 2/20 0.37
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
CYP17A1 P05093 3/20 0.35
PDE2A O00408 1/20 0.35
PDE7A Q13946 1/20 0.35
HTR7 P34969 1/20 0.35
P2RX7 Q99572 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467559 0.89 HTR2A (0.41) HTR2AHTR2CHTR2BCYP11B2GRM2
SCHEMBL793293 0.81 CYP11B2 (0.61) HTR2AHTR2CHTR2BCYP11B2GRM2
SCHEMBL793449 0.80 PARP1 (0.42) HTR2AHTR2CHTR2BCYP11B2PDE10A
SCHEMBL27901760 0.74 HTR2A (0.36) HTR2AHTR2CHTR2BPDE10ACYP17A1
SCHEMBL793461 0.73 CYP11B2 (0.43) HTR2AHTR2CHTR2BCYP11B2PDE10A
SCHEMBL807761 0.72 CYP11B2 (0.40) CYP11B2GRM2PDE10APARP1PARP10
SCHEMBL793423 0.70 PARP1 (0.43) HTR2AHTR2CHTR2BCYP11B2PARP1
SCHEMBL794272 0.69 PHGDH (0.43) HTR2AHTR2CPDE10A
SCHEMBL793875 0.69 TRPV3 (0.41) HTR2AHTR2CPDE10A
SCHEMBL793796 0.69 CYP17A1 (0.58) CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US claimed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP claimed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO claimed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 HTR2A 3716/4885HTR2C 2446/4885HTR2B 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.